Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 01 Sep 2016
Live national webcast of review of pharmacy remuneration and regulation
1 September 2016 - The review panel will host a live national webcast from Canberra on 7 September 2016 at 7:00pm ...
Posted by Michael Wonder on 31 Aug 2016
Q&A: Is NZ lagging in cancer drug funding?
31 August 2016 - Researchers have called for an urgent overhaul of New Zealand's processes for funding cancer drugs to ensure ...
Posted by Michael Wonder on 31 Aug 2016
Schedule of Pharmaceutical Benefits - 1 September 2016 update
1 September 2016 - The 1 September 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 31 Aug 2016
New Zealand Pharmaceutical Schedule - 1 September 2016 update
1 September 2016 - The September 2016 issue of the New Zealand Pharmaceutical Schedule sees the listing of one new ...
Posted by Michael Wonder on 30 Aug 2016
Agenda for the 7 September 2016 TC meeting
30 August 2016 - The Transparency Commission will reconvene early next month after the summer break to review a few new ...
Posted by Michael Wonder on 30 Aug 2016
Decision to award sole supply to Zoladex and reference price Eligard and Lucrin
30 August 2016 - PHARMAC has made decisions to award the Zoladex brand of goserelin acetate sole subsidised supply in the ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends Brilinta (ticagrelor)
25 August 2016 - CADTH has recommended the reimbursement of AstraZeneca's Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events. ...
Posted by Michael Wonder on 30 Aug 2016
CADTH recommends the reimbursement of Invokamet (canagliflozin hemihydrate with metformin hydrochloride)
25 August 2016 - CADTH has published its final recommendation on the reimbursement of Invokamet in Canada. ...
Posted by Michael Wonder on 29 Aug 2016
CADTH recommends against the reimbursement of Egrifta (tesamorelin acetate)
24 August 2016 - CADTH is not convinced that Egrifta should be reimbursed in Canada. ...
Posted by Michael Wonder on 29 Aug 2016
CADTH recommends the reimbursement of Descovy (emtricitabine with tenofovir alafenamide fumarate)
24 August 2016 - CADTH is in favour of the reimbursement of Gilead's new dual combination product for HIV-1 infection. ...
Posted by Michael Wonder on 28 Aug 2016
Cancer campaigner and melanoma patient Jeffrey Paterson dies aged 23
28 August 2016 - Young melanoma patient Jeffrey Paterson helped to win the campaign for Government funding of Keytruda, but didn't ...
Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of secukinumab (Cosentyx) for ankylosing spondylitis
23 August 2016 - CADTH publishes second outcome for Cosentyx this month. ...
Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of Truvada for PrEP
24 August 2016 - The recommendation comes with conditions. ...
Posted by Michael Wonder on 26 Aug 2016
NICE backs non-surgical option for fibroids
26 August 2016 - Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the NHS for ...